Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... According to the new research ... (Image Analysis Software), Delivery Modes (Web Based/Cloud Based) & ... to 2018", published by MarketsandMarkets, analyzes and studies the ... North America , Europe ... Rest of the World (RoW). Browse 78 ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, ... with FORMA Therapeutics, Inc., to provide access to ... fragment-based lead discovery platform for novel small molecule ... about the opportunity to work with FORMA Therapeutics ... epigenetics and protein homeostasis. FORMA Therapeutics, decision to ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, applauds ... for taking a strong position in opposition to ... July 27, 2014 publication.  The New York Times ... articles this week exploring the issue called "High ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... , , , , , , ... Silvia Svegliati, Michele Luchetti, and Armando Gabrielli , ... Scientifico, Ancona, Italy , , ... , GC-rich sequences difficult to amplify by PCR. This ...
... , , , , ... up to 24 automated large-scale 6xHis-tagged , protein ... workstation. Using cleared lysates from bacterial cultures as starting material, ... can be purified under native or denaturing , ...
... , , , High-quality ... efficient gene silencing in eukaryotic cell culture by targeting complementary , ... , gene silencing in functional genomics studies. Now, ... service that includes a range of modifications , ...
Cached Biology Technology:Successful PCR amplification and subcloning of a GC-rich DNA fragment 2Successful PCR amplification and subcloning of a GC-rich DNA fragment 3Successful PCR amplification and subcloning of a GC-rich DNA fragment 4Successful PCR amplification and subcloning of a GC-rich DNA fragment 5Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 2Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 3Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 4Custom and library siRNA for efficient gene silencing 2Custom and library siRNA for efficient gene silencing 3Custom and library siRNA for efficient gene silencing 4Custom and library siRNA for efficient gene silencing 5
(Date:7/29/2014)... from scientists at the University of Kent has shown ... are regulated a breakthrough that could have a ... from Kent,s School of Biosciences uncovered the mechanism whereby ... known as actin filaments are ,fine-tuned, to ... filaments appear to completely stable, providing a framework for ...
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/28/2014)... Amundsen reached the South Pole in 1911, but new ... any human. , Using data from 16 ice cores ... including the South Pole, a group led by Joe ... Nevada, created the most accurate and precise reconstruction to ... new record, described in an article published today in ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... to check out the complete report on the HIV ... new evidence that adult HIV infection rates have decreased in ... as increased use of condoms, delay of first sexual experience ... declines. The new UN report also indicates, however, that overall ...
... Drinking a shot of smooth full-flavoured brandy this Christmas ... found. , Dr Gordon Troup from the School of ... to have supplementary medicinal health benefits ?and the better ... key to its benefit is antioxidants contained in the ...
... numerous problems in Russia, not the least of which ... ongoing study of 25- to 54-year-old Russian men living ... significant proportion consume "surrogate" alcohols, otherwise known as products ... Researchers have now analyzed the contents of these ...
Cached Biology News:Earliest European Farmers Left Little Genetic Mark On Modern Europe 2Earliest European Farmers Left Little Genetic Mark On Modern Europe 3Earliest European Farmers Left Little Genetic Mark On Modern Europe 4Russian 'surrogate' alcohols are a killer 2Russian 'surrogate' alcohols are a killer 3Russian 'surrogate' alcohols are a killer 4
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
MAGP-2 (C-19)...
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
TGF-beta 2 MAb (Clone 8607)...
Biology Products: